James Rogers James Rogers is a Financial Columnist for MarketWatch.
funds
Opinion: Biotech is back. Here’s why these rallying stocks belong in your portfolio now.
Published: Nov. 3, 2025 at 9:58 a.m. ET Biotech stocks are emerging from a four-year slump. The…
Investors are piling into bonds amid worries over a high-flying stock market
Investors are hungrier than ever for bonds in the ETF industry amid worries over stretched valuations…